Helicobacter pylori is an important human pathogenic bacterium associated with numerous severe gastroduodenal diseases, including ulcers and gastric cancer. Cytosolic leucyl aminopeptidase (LAP) is an important housekeeping protein that is involved in peptide and protein turnover, catabolism of proteins and modulation of gene expression. LAP is upregulated in metronidazole-resistant H. pylori, which suggests that, in addition to having an important housekeeping role, LAP contributes to the mechanism of drug resistance. Crystals of H. pylori LAP have been grown by the hanging-drop vapour-diffusion method using polyethylene glycol as a precipitating agent. The crystals belonged to the primitive triclinic space group P1, with unit-cell parameters a = 97.5, b = 100.2, c = 100.4 Å , = 75.4, = 60.9, = 81.8 . An X-ray diffraction data set was collected to 2.8 Å resolution from a single crystal. Molecular-replacement results using these data indicate that H. pylori LAP is a hexamer with 32 symmetry.
Introduction
Helicobacter pylori colonizes the stomachs of roughly 50% of the population and is associated with numerous severe gastroduodenal diseases, including gastric and duodenal ulcers and gastric adenocarcinoma (Marshall & Warren, 1984; Uemura et al., 2001; Peek & Blaser, 2002) . The eradication of H. pylori reduces the recurrence of gastric cancer in patients who have received endoscopic resection of early cancer and the recurrence of ulcers in patients with peptic ulcer disease (Ford et al., 2011; Uemura et al., 1997) . At present, there is no specific single drug that can effectively cure H. pylori infection; current treatments involve the use of a combination of a protonpump inhibitor with two broad-spectrum antibiotics (mainly clarithromycin and either amoxicillin or metronidazole; Treiber et al., 1998) . An increasing prevalence of resistance to the antibiotic components of such regimens (Broutet et al., 2003) requires better understanding of the molecular mechanisms of H. pylori pathogenesis and the identification of new drug targets for the development of effective anti-Helicobacter agents.
Cytosolic leucyl aminopeptidase (LAP, leucine aminopeptidase, cathepsin III; EC 3.4.11.1), found in many microorganisms, plants and animals, catalyses the removal of N-terminal leucine residues and, at a lower frequency, other amino-acid residues from peptides and proteins. LAPs are classified into two families, M1 and M17, which have distinctly different structures, catalytic mechanisms and biological roles (for a review, see Matsui et al., 2006) . LAPs are important housekeeping proteins that are involved in many essential physiological processes such as peptide and protein turnover, catabolism of endogenous and exogenous proteins, modulation of gene expression and antigen processing (Matsui et al., 2006) . Analysis of the crystal structures of LAPs from Escherichia coli (Strä ter et al., 1999) , bovine eye lens (Burley et al., 1991) , Pseudomonas putida (Kale et al., 2010) and Plasmodium falciparum (McGowan et al., 2010) revealed that LAPs in peptidase family M17 have two globular / domains: a smaller variable N-terminal domain and a larger conserved C-terminal domain that contains the active site. Their activities require two metal ions and are inhibited by bestatin.
LAP from H. pylori is a 54.3 kDa protein that is upregulated in metronidazole-resistant H. pylori (Kaakoush et al., 2009) , which suggests that, in addition to having an important housekeeping role, LAP contributes to the mechanism of drug resistance. H. pylori LAP shows low similarity to other members of the M17 family of metallopeptidases with, for example, only 26 and 24% amino-acid sequence identity to the LAPs from E. coli and human, respectively (Dong et al., 2005) . Despite the low level of sequence homology, the residues essential for the metal binding and catalytic activity of M17 LAPs are conserved in H. pylori LAP (Dong et al., 2005) , suggesting a common catalytic mechanism for this enzyme. Previous kinetic studies showed that H. pylori LAP is an allosteric enzyme with sigmoid rather than hyperbolic velocity versus substrate-concentration plots (Dong et al., 2005) . This clearly distinguishes the H. pylori enzyme from most of the other known M17 LAPs, which generally show Michaelis-Menten saturation kinetics (Thierry & Janine, 1996) . In this paper, we report the cloning, purification, crystallization and preliminary X-ray analysis of recombinant H. pylori LAP in complex with bestatin. Analysis of the crystal structure of this enzyme would be an important step towards understanding the structural basis of its unique allosteric behaviour.
Materials and methods

Cloning and overexpression
The coding sequence for LAP (UniProtKB ID O25294) was PCRamplified from genomic DNA of strain 26695 of H. pylori using Pfu DNA polymerase (Stratagene) and the primers CACCTTAAAA-ATCAAATTAGAAAAAACCAC (forward) and TCAAGCCTTT-TTCAAAAGCTC (reverse). The amplified fragment was cloned into the pET151/D-TOPO vector using the TOPO cloning kit (Invitrogen) to produce an expression vector that contains an N-terminal His 6 tag followed by a TEV protease cleavage site. The expression clone was confirmed by DNA sequencing. The recombinant protein used for crystallization comprised residues 1-495 of LAP plus six additional residues from the TEV protease cleavage site and vector (GIDPFT). The vector was transformed into E. coli strain BL21(DE3) (Novagen). The cells were grown in LB medium containing 50 mg l À1 ampicillin at 310 K until an OD 600 of 0.8 was reached, at which point overexpression of LAP was induced by adding 0.5 mM IPTG and growth was continued for a further 3 h. The cells were then harvested by centrifugation at 6000g for 15 min at 277 K.
Purification
The cells were resuspended in buffer A (20 mM sodium phosphate pH 7.4, 200 mM NaCl, 1 mM PMSF) and lysed by sonication. Cell debris was removed by centrifugation at 12 000g for 30 min at 277 K. The supernatant was collected and clarified by ultracentrifugation at 105 000g for 20 min at 277 K. NaCl and imidazole were then added to the supernatant to final concentrations of 500 and 10 mM, respectively, after which the supernatant was loaded onto a 5 ml HiTrap Chelating HP column (GE Healthcare) pre-washed with buffer A containing 500 mM NaCl. The column was washed with 20 column volumes of buffer B (20 mM sodium phosphate pH 7.4, 500 mM NaCl, 60 mM imidazole) and the protein was eluted with buffer B containing 500 mM imidazole. The N-terminal tag was cleaved off with His 6 -TEV protease (Invitrogen) overnight at 277 K whilst dialysing the sample against buffer C [50 mM Tris-HCl pH 8.0, 2 mM DTT, 200 mM NaCl, 1%(v/v) glycerol]. NaCl and imidazole were then added to the sample to final concentrations of 500 and 15 mM, respectively, and the TEV protease and uncleaved protein were removed on a HiTrap Chelating HP column. The flowthrough was concentrated to 2 ml in a Vivaspin 30 000 Da cutoff concentrator and passed through a Superdex 200 HiLoad 26/60 gel-filtration column (GE Healthcare) equilibrated with buffer D (50 mM HEPES pH 8.0, 200 mM NaCl). The protein concentration was determined using the Bradford assay (Bradford, 1976) . The protein purity was estimated to be greater than 98% (Fig. 1) .
Crystallization and preliminary X-ray analysis
Prior to crystallization, the protein was concentrated to 14.3 mg ml À1 , mixed with bestatin (final concentration 1 mM) and centrifuged for 20 min at 13 000g to clarify the solution. Initial screening of crystallization conditions was carried out by the hanging-drop vapourdiffusion method using an automated Phoenix crystallization robot (Art Robbins Instruments) and Crystal Screen HT and PEG/Ion HT (Hampton Research). The initial crystallization droplets consisted of 100 nl protein solution mixed with 100 nl reservoir solution and were equilibrated against 50 ml reservoir solution in a 96-well Art Robbins CrystalMation Intelli-Plate (Hampton Research). Crystals appeared after 2 d from condition No. 78 of Crystal Screen HT, which consisted of 10%(w/v) polyethylene glycol (PEG) 6000, 5%(v/v) 2-methyl-2,4-pentanediol (MPD), 100 mM HEPES pH 7.5. This condition was subsequently refined to improve the quality of the crystals, yielding optimal PEG 6000, protein and bestatin concentrations of 9%(v/v), 9.2 mg ml À1 and 1 mM, respectively. For data collection, the crystals were flash-cooled to 100 K after soaking in a cryoprotectant solution consisting of 12%(w/v) PEG 6000, 6%(v/v) MPD, 100 mM HEPES pH 7.5, 2 mM bestatin, 25%(v/v) glycerol. X-ray data were collected from the crystal to 2.8 Å resolution using a Rigaku MicroMax-007 microfocus rotating-anode generator and a Rigaku R-AXIS IV imaging-plate detector. A total of 220 images were collected using 0.5 oscillations. The data were processed and scaled using d*TREK (Pflugrath, 1999) . The statistics of data collection are summarized in Table 1 .
Molecular replacement
In a search for a suitable model for molecular replacement, a sequence-similarity search against the structures deposited in the RCSB Protein Data Bank was performed. The two most similar sequences were those of LAPs from P. putida and E. coli (Strä ter et al., 1999; Kale et al., 2010) . The 495-residue LAP from H. pylori shares 35% identity with both the 497-residue LAP from P. putida and the 503-residue LAP from E. coli in a 375-residue overlap. Molecular replacement was performed with the Phaser program (McCoy et al., 2005) using all data to 2.8 Å resolution. The search model was prepared using CHAINSAW (Stein, 2008) based on the coordinates of P. putida LAP (PDB entry 3h8g; Kale et al., 2010) .
Results and discussion
Overexpression, purification and biochemical characterization
Recombinant H. pylori LAP was expressed from the pET151/ D-TOPO plasmid in E. coli BL21(DE3) upon induction of T7 polymerase. The enzyme was purified to >98% electrophoretic homogeneity based on Coomassie Blue staining of SDS-PAGE gels (Fig. 1) . The protein migrated on SDS-PAGE with an apparent molecular weight of 53 kDa, which is close to the value calculated from the amino-acid sequence (54.3 kDa).
When subjected to gel filtration, the protein eluted as a single peak with an apparent molecular weight of approximately 260 kDa (Fig. 2) , indicating that H. pylori LAP forms an oligomer in solution. The particle weight value estimated from the mobility of the gel-filtration column was approximately midway between the calculated masses of a tetramer (217.2 kDa) and a hexamer (325.8 kDa). Previous studies of LAPs from different plants, animals and microorganisms consistently reported a hexameric state for this family of enzymes (Matsui et al., 2006; Stack et al., 2007) . The elution profile of H. pylori LAP is therefore likely to represent a hexamer rather than a tetramer.
Crystallization and preliminary crystallographic analysis
Crystals of the H. pylori LAP-bestatin complex (Fig. 3) were obtained using a sparse-matrix crystallization approach. Test data collected from a cryocooled crystal using an in-house Rigaku rotating-anode generator showed diffraction to 2.5 Å resolution crystallization communications Figure 2 Gel-filtration trace of purified recombinant H. pylori LAP. The molecular weight was determined from a calibration plot of log(molecular weight) (log MW) versus the retention volume [V retention (ml) = 549.3 À 73.9 Â log MW] available at the EMBL Protein Expression and Purification Core Facility website (http:// www.embl.de/pepcore/pepcore_services/protein_purification/chromatography/ hiload26-60_superdex200/index.html).
Figure 3
Crystals of the H. pylori LAP-bestatin complex.
Figure 4
A representative 0.5 oscillation image of the data collected using an in-house Rigaku rotating-anode generator. The arrow indicates reflections at 2.5 Å resolution.
( Fig. 4) . Analysis of the diffraction data using the autoindexing routine in d*TREK showed that the crystals belonged to the primitive triclinic space group P1, with unit-cell parameters a = 97.5, b = 100.2, c = 100.4 Å , = 75.4, = 60.9, = 81.8 . The V M value calculated under the assumption of a hexamer in the asymmetric unit was 2.54 Å 3 Da À1 , which falls within the range observed for protein crystals (Matthews, 1968 ) and corresponds to a solvent content of approximately 52%. A molecular-replacement search was performed using Phaser with a monomer of P. putida LAP as a model. Six copies of the search model were found in the asymmetric unit, which made up a hexamer with 32 symmetry that was very similar to the hexamers observed in the crystals of the LAPs from P. putida and E. coli (Kale et al., 2010; Strä ter et al., 1999) , indicating that the molecularreplacement solution is correct. Attempts to optimize the crystal quality and collect higher resolution diffraction data and structure refinement are currently in progress.
